Related Experiment Video
Updated: Jul 4, 2025
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Mycoplasma genitalium: Key Information for the Primary Care Clinician
Oluyomi A Obafemi1, Sarah E Rowan2, Masayo Nishiyama3
1Public Health Institute at Denver Health, 601 Broadway, 8th Floor, MC 2800, Denver, CO 80203-3407, USA; Department of Family Medicine, University of Colorado Denver, Aurora, CO, USA.
Abstract:
Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, which appears to be a cause of urethritis and cervicitis and has been associated with pelvic inflammatory disease (PID), epididymitis, proctitis, infertility, complications during pregnancy, and human immunodeficiency virus (HIV) transmission. Three Food and Drug Administration (FDA) approved tests are available. Testing should be focused to avoid inappropriate antibiotic use. The Center of Disease Control and Prevention (CDC) guidelines recommend testing for persistent male urethritis, cervicitis, and proctitis and state that testing should be considered in cases of PID. Testing is also recommended for sexual contacts of patients with MG. Testing is not recommended in asymptomatic patients, including pregnant patients, who do not have a history of MG exposure. Although resistance-guided therapy is recommended, there are currently no FDA approved tests for MG macrolide resistance, and tests are not widely available in the United States. The CDC recommends 2-step treatment with doxycycline followed by azithromycin or moxifloxacin. Moxifloxacin is recommended if resistance testing is unavailable or testing demonstrates macrolide resistance..
Insights
Mycoplasma genitalium (MG) is a growing sexually transmitted infection linked to various reproductive health issues. Targeted testing is advised to prevent unnecessary antibiotic use, with specific recommendations for symptomatic individuals and their contacts.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Mycoplasma genitalium (MG) is an emerging sexually transmitted infection (STI).
- MG is associated with urethritis, cervicitis, pelvic inflammatory disease (PID), and adverse pregnancy outcomes.
- It is also linked to infertility and increased human immunodeficiency virus (HIV) transmission risk.
Purpose of the Study:
- To outline current diagnostic and treatment guidelines for Mycoplasma genitalium infections.
- To emphasize the importance of targeted testing to optimize antibiotic stewardship.
- To address challenges related to antimicrobial resistance in MG treatment.
Main Methods:
- Review of current Food and Drug Administration (FDA)-approved diagnostic tests for MG.
- Analysis of Centers for Disease Control and Prevention (CDC) testing recommendations.
- Examination of treatment strategies, including resistance-guided therapy.
Main Results:
- Three FDA-approved tests for MG are available.
- CDC guidelines recommend testing for specific symptomatic conditions (urethritis, cervicitis, proctitis, PID) and sexual contacts.
- Testing is not recommended for asymptomatic individuals without known exposure.
- No FDA-approved tests for MG macrolide resistance are currently available in the US.
Conclusions:
- Targeted testing for Mycoplasma genitalium is crucial to guide appropriate antibiotic use.
- Current treatment guidelines recommend a two-step approach, with macrolide resistance necessitating alternative therapies like moxifloxacin.
- Further development of resistance testing is needed to support resistance-guided therapy.
Related Concept Videos
01:26Sexually Transmitted Infections
01:20Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...